Maria Emilia Seren Takahashi

Dr. Maria Emilia Seren Takahashi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MTMaria Emilia Seren Takahashi
Maria Emilia Seren Takahashi
CMCamila Mosci
Camila Mosci
ESEdna M. Souza
Edna M. Souza
SBSérgio Q. Brunetto
Sérgio Q. Brunetto
EEElba Etchebehere
Elba Etchebehere
CRCelso Dario Ramos
Celso Dario Ramos
Many efforts have been made to standardize the interpretation of 18F-FDG PET/CT in multiple myeloma (MM) with qualitative visual analysis or with quantitative metabolic parameters using various methods for lesion segmentation of PET images. The aim of this study was to propose a quantitative method for bone and bone marrow evaluation of 18F-FDG PET/CT considering the extent and intensity of bone 18F-FDG uptake: Intensity of Bone Involvement (IBI). Whole body 18F-FDG PET/CT of 59 consecutive MM patients were evaluated. Compact bone tissue was segmented in PET images using a global threshold for HU of the registered CT image. A whole skeleton mask was created and the percentage of its volume with 18F-FDG uptake above hepatic uptake was calculated (Percentage of Bone Involvement - PBI). IBI was defined by multiplying PBI by mean SUV above hepatic uptake. IBI was compared with visual analysis performed by two experienced nuclear medicine physicians. IBI calculation was feasible in all images (range:0.00–1.35). Visual analysis categorized PET exams into three groups (negative/mild, moderate and marked bone involvement), that had different ranges of IBI (multi comparison analysis, p < 0.0001). There was an inverse correlation between the patients’ hemoglobin values and IBI (r = −0.248;p = 0.02). IBI score is an objective measure of bone and bone marrow involvement in MM, allowing the categorization of patients in different degrees of aggressiveness of the bone disease. The next step is to validate IBI in a larger group of patients, before and after treatment and in a multicentre setting.

1 June 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
AJAdemar Dantas da Cunha Júnior
Ademar Dantas da Cunha Júnior
MSMarina Nogueira Silveira
Marina Nogueira Silveira
MTMaria Emilia Seren Takahashi
Maria Emilia Seren Takahashi
ESEdna Marina de Souza
Edna Marina de Souza
CMCamila Mosci
Camila Mosci
JCJosé Carvalheira
José Carvalheira

12 February 2020 in Nuclear Medicine Communications
Verified
Journal Article
Open access
MTMaria Emilia Seren Takahashi
Maria Emilia Seren Takahashi
CMCamila Mosci
Camila Mosci
ESEdna M. Souza
Edna M. Souza
SBSérgio Q. Brunetto
Sérgio Q. Brunetto
CSCármino de Souza
Cármino de Souza
CRCelso Dario Ramos
Celso Dario Ramos
Purpose: Quantifications in nuclear medicine are occasionally limited by the lack of standardization for defining volumes of interest (VOIs) on functional images. In the present article, we propose the use of computed tomography (CT)–based skeletal segmentation to determine anatomically the VOI in order to calculate quantitative parameters of fluorine 18 fluorodeoxyglucose (18F-FDG) PET/CT images from patients with multiple myeloma. Methods: We evaluated 101 whole-body 18F-FDG PET/CTs of 58 patients with multiple myeloma. An initial subjective visual analysis of the PET images was used to classify the bone involvement as negative/mild, moderate, or marked. Then, a fully automated CT–based segmentation of the skeleton was performed on PET images. The maximum, mean, and SD of the standardized uptake values (SUVmax, SUVmean, and SDSUV) were calculated for bone tissue and compared with the visual analysis. Results: Forty-five (44.5%), 32 (31.7%), and 24 (23.8%) PET images were, respectively, classified as negative/mild, moderate, or marked bone involvement. All quantitative parameters were significantly related to the visual assessment of bone involvement. This association was stronger for the SUVmean [odds ratio (OR): 10.52 (95% confidence interval (CI), 5.68–19.48); P < 0.0001] and for the SDSUV [OR: 5.58 (95% CI, 3.31–9.42); P < 0.001) than for the SUVmax [OR: 1.01 (95% CI, 1.003–1.022); P = 0.003]. Conclusion: CT–based skeletal segmentation allows for automated and therefore reproducible calculation of PET quantitative parameters of bone involvement in patients with multiple myeloma. Using this method, the SUVmean and its respective SD correlated better with the visual analysis of 18F-FDG PET images than SUVmax. Its value in staging and evaluating therapy response needs to be evaluated.

11 October 2019 in Journal of Nuclear Medicine Technology
Verified
Journal Article
Closed access
PDF file
MCMariana Ramos Camacho
Mariana Ramos Camacho
EEElba Etchebehere
Elba Etchebehere
NTNatalia Tardelli
Natalia Tardelli
MDMarcia Torresan Delamain
Marcia Torresan Delamain
AVAlinne Fernanda Amaral Verçosa
Alinne Fernanda Amaral Verçosa
CRCelso Dario Ramos
Celso Dario Ramos
Introduction: Quantification of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) can be time-consuming. We evaluated the performance of an automatic multi-foci segmentation method of quantification (MFS) in patients with different stages of Hodgkin`s Lymphoma, using the multiple VOI method (MV) as reference. Methods: This prospective bicentric study included 50 patients with Hodgkin’s Lymphoma who underwent staging 18F-FGD PET/CT. The exams were centrally reviewed and processed with commercial MFS software in order to obtain MTV and TLG utilizing two fixed relative thresholds (40% and 20% of the maximum standardized uptake value) of each lesion. All PET/CTs were processed using the MV and MFS methods. Inter-class correlation coefficient and Bland & Altman plots were used for statistical analysis. Repeated calculations of MTV and TLG values by two observers with different degrees of PET/CT imaging experience were used to access interobserver agreement of the MFS method. Results: The mean and standard deviation values obtained for the MTV with MV and MFS were respectively 736mL ± 856mL and 660mL ± 699mL for the 20% threshold, and 313mL ± 359mL and 372mL ± 434mL for the 40% threshold. The time spent calculating the MTV was much shorter with the MFS than with the MV method (median time: 11.6 min. [1-30 min] and 64.4min. [1-240 min], respectively), especially in patients with advanced disease. Time spent was similar in patients with localized disease. There were no statistical differences between the MFS values obtained by the two different observers. Conclusion: MTV and TLG calculations using MFS are reproducible, generate similar results to those obtained with MV and are much less timing consuming. Main differences between the two methods were related to difficulties in avoiding overlay of VOIs in the MV technique. MV and MFS perform equally well in in patients with small number of lesions.

23 July 2020 in Nuclear Medicine Communications
Verified
Journal Article
Open access
CMCamila Mosci
Camila Mosci
FPFernando V. Pericole
Fernando V. Pericole
GOGislaine B. Oliveira
Gislaine B. Oliveira
MDMarcia T. Delamain
Marcia T. Delamain
MTMaria Emilia Seren Takahashi
Maria Emilia Seren Takahashi
CRCelso Dario Ramos
Celso Dario Ramos
Purpose: 18 F-fluorodeoxiglucose ( 18 F-FDG)-PET/CT has been widely used to evaluate multiple myeloma. 99m Tc-sestamibi (MIBI) scintigraphy has also been proposed for assessing multiple myeloma, but its use with state-of-the-art single-photon emission computed tomography/computed tomography (SPECT/CT) technology has not been fully evaluated.This study aimed to compare these two imaging modalities in multiple myeloma staging. Materials and methods: Sixty-two patients with recently diagnosed multiple myeloma were submitted to whole-body 18 F-FDG-PET/CT and whole-body MIBI scans plus SPECT/CT of the chest and abdomen/pelvis. Number of focal lesions, contiguous soft tissue involvement (CSTI), extramedullary lesions (EMLs) and diffuse bone marrow (BM) involvement were recorded. Results: PET/CT was positive in 59 patients (95%) and MIBI SPECT/CT in 58 (93%) ( P = 0.69). MIBI detected more diffuse bone marrow involvement than PET/CT (respectively 78 vs. 58% of the patients), while PET/CT demonstrated more focal lesions than MIBI SPECT/CT (81 vs. 54% of the patients) ( P = 0.002). PET/CT detected EMLs in four subjects and MIBI in one subject. CSTI was found in 28 (45%) and 23 (37%) patients on PET/CT and MIBI images, respectively ( P = 0.36). Three patients with lytic lesions and no FDG uptake were MIBI positive, and two subjects with lytic lesions without MIBI uptake were FDG positive. Conclusion: MIBI SPECT/CT performs similarly to 18 F-FDG-PET/CT in identifying sites of active disease in multiple myeloma staging. MIBI is more efficient than FDG for detecting the diffuse involvement of bone marrow but less efficient for detecting focal lesions. Some patients presented a ‘mismatch’ pattern of FDG/MIBI uptake.

29 March 2023 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SSStephan P. M. Souza
Stephan P. M. Souza
FFFernanda C. Frasson
Fernanda C. Frasson
MTMaria Emilia Seren Takahashi
Maria Emilia Seren Takahashi
GDGislaine B. O. Duarte
Gislaine B. O. Duarte
VCVania P. Castro
Vania P. Castro
CRCelso Dario Ramos
Celso Dario Ramos